Medical Innovation Ecosystem

Some alarmists complain that the cost of new, innovative cancer treatments will soon bankrupt the health care system, arguing that we must find a way to limit patients' access to them. When we point out that the new treatments represent only 0.5% (one half of one percent) of health care costs, those people claim that it doesn't matter, because the expense of new treatments is increasing at an increasing rate, and we must do something. Horsefeathers, I say. The sky is not falling. Instead, the system is working just as it should, exactly as designed. A company innovates, inventing a new treatment and, after years of trials and against tall odds, finally makes a good, healthy profit on a treatment that saves and extends lives. This provides the financial and technological footing upon which that company can further innovate, advancing medical understanding to create an even better treatment, or a new treatment for another disease. The medical innovation ecosystem also includes governments, academia, research hospitals, and more, but the pharmaceutical companies always do the heavy lifting. That's the system we have, and it's working. Let's not mess with it. Deep in discussion at ASCO Costs of new treatments may indeed rise, but those new treatments will increasingly keep us out of hospitals and clinics, reducing those costs. Further, we will lead healthier, more productive lives, earning and spending, thereby contributing to the economy. Even more, as innovation extends ou...
Source: Myeloma Hope - Category: Cancer Tags: ASCO Medical Innovation Ecosystem My Life Is Worth It petition Source Type: blogs

Related Links:

ConclusionLncRNA MALAT1 expedited MM tumorigenesis, invasion, and glycolysis via miR-1271-5p/SOX13 axis. MALAT1 might contribute to the therapy of MM as a promising indicator.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
sabeth Ersvær Immunomodulatory drugs (IMiDs) are used in the treatment of hematological malignancies, especially multiple myeloma. IMiDs have direct anticancer effects but also indirect effects via cancer-supporting stromal cells. Monocytes are a stromal cell subset whose metabolism is modulated by the microenvironment, and they communicate with neighboring cells through extracellular release of soluble mediators. Toll-like receptor 4 (TLR4) is then a common regulator of monocyte metabolism and mediator release. Our aim was to investigate IMiD effects on these two monocyte functions. We compared effects of thalid...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
CONCLUSIONS: Our findings indicate that combined blockade of PD-1 and TGF-b may be useful for the treatment of MM. PMID: 31941832 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
After the Twin Towers fell on Sept. 11, 2001, the thousands of people involved in rescue-and-cleanup efforts were exposed to carcinogens and other toxins as they breathed in contaminated air and dug through industrial rubble. Studies completed since then have shown elevated rates of conditions including multiple myeloma, prostate cancer and thyroid cancer among 9/11 responders and those who worked near the site. A new study published Jan. 14 in the journal JNCI Cancer Spectrum adds another to that list: leukemia. “After about 12 years of follow-up, there was an increase in the rate of all cancers combined, and separa...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Cancer Research Source Type: news
CONCLUSIONS: This study provides the basis for studying the addition of JAK inhibitors to improve the efficacy of immunomodulatory agents with steroids for treating myeloma patients but perhaps can also be expanded for treating other cancer patients that are refractory to this class of drugs. PMID: 31937615 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
ConclusionsThis study is one of the first to apply the EORTC QLU-C10D to a heterogeneous group of cancer patients. Results can be used to more efficiently target care towards factors influencing HRQoL. Furthermore, it enhances our understanding of how the EORTC QLU-C10D performs across cancer types, supporting its use in cost –utility analyses.
Source: Quality of Life Research - Category: Health Management Source Type: research
SUMMARY The increasing prevalence of neoplasias is associated with new clinical challenges, one of which is acute kidney injury (AKI). In addition to possibly constituting a clinical emergency, kidney failure significantly interferes with the choice and continuation of antineoplastic therapy, with prognostic implications in cancer patients. Some types of neoplasia are more susceptible to AKI, such as multiple myeloma and renal carcinoma. In cancer patients, AKI can be divided into pre-renal, renal (intrinsic), and post-renal. Conventional platinum-based chemotherapy and new targeted therapy agents against cancer are exampl...
Source: Revista da Associacao Medica Brasileira - Category: General Medicine Source Type: research
Contributors : Ali M Shirayeh ; Rodger E TiedemannSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Homo sapiensChromosome copy number variations (CNV) are a near-universal feature of cancer however their specific effects on cellular function are poorly understood. Single-cell RNA sequencing (scRNA-seq) can reveal cellular gene expression however cannot directly link this to CNVs. Here we report scRNA-seq normalization methods that improve inter-cellular expression alignment, increasing the sensitivity of scRNA-seq for CNV detection. We additionally report sciCNV, a tool for inferring CNVs ...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Other Homo sapiens Source Type: research
Whole-body diffusion weighted imaging (WB-DWI) has proven value to detect multiple myeloma (MM) lesions. However, the large volume of imaging data and the presence of numerous lesions makes the reading process...
Source: Cancer Imaging - Category: Radiology Authors: Tags: Research article Source Type: research
erpos Thromboembolism in multiple myeloma (MM) patients remains a common complication that renders the optimization of our thromboprophylaxis practice necessary. This review aims to make clear the need for the development of more accurate risk assessment tools and means of thrombosis prevention. Current clinical practice is guided by available guidelines published by the IMWG in 2014, but the extent to which these are implemented is unclear. Recently, several groups developed clinical scores for thrombosis risk in MM in an attempt to improve risk stratification, but these have not been validated or used in clinical pra...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
More News: Academia | Cancer | Cancer & Oncology | Economy | Health | Health Management | Hospitals | Insurance | Legislation | Medical Ethics | Medical Law | Myeloma